List of Excipients in Branded Drug DAPTOMYCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	DAPTOMYCIN	daptomycin	0143-9455	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	DAPTOMYCIN	daptomycin	0143-9456	ARGININE
Hikma Pharmaceuticals USA Inc	DAPTOMYCIN	daptomycin	0143-9456	HISTIDINE
Hikma Pharmaceuticals USA Inc	DAPTOMYCIN	daptomycin	0143-9456	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	DAPTOMYCIN	daptomycin	0143-9456	ISOLEUCINE
Hospira Inc	DAPTOMYCIN	daptomycin	0409-0122	ANHYDROUS CITRIC ACID

Generic Drugs Containing DAPTOMYCIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	daptomycin	0143-9378	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	daptomycin	0143-9444	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	daptomycin	0143-9465	SODIUM HYDROXIDE
Hospira Inc	daptomycin	0409-2757	SODIUM HYDROXIDE
Sandoz Inc	daptomycin	0781-3295	SODIUM HYDROXIDE
NorthStar RxLLC	daptomycin	16714-892	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in DAPTOMYCIN?

# Of NDCs	Excipient
1	NITROGEN
38	SODIUM HYDROXIDE
1	SUCROSE
2	WATER

Daptomycin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Daptomycin is a mature intravenous lipopeptide antibiotic with broad generic availability and limited remaining value in the original active-ingredient patent estate. The strongest commercial opportunities are formulation and delivery improvements that reduce preparation time, improve refrigerated or room-temperature stability, support outpatient administration, and lower medication-error risk.

The core product is a sterile, lyophilized powder for intravenous infusion. Original Cubicin and generic products generally use a simple excipient system centered on sodium hydroxide for pH adjustment. Some presentations, including Cubicin RF, use sucrose as a bulking or stabilizing excipient. The formulation field remains commercially relevant because daptomycin has compatibility, reconstitution, adsorption, aggregation, and stability constraints.[1-3]

What excipients are used in daptomycin products?

Daptomycin injectable products typically contain few excipients. The exact composition depends on the manufacturer and presentation.

Product type	Typical active ingredient	Representative excipients	Primary function
Original daptomycin lyophilized vial	Daptomycin	Sodium hydroxide; in some products, sucrose	pH adjustment, cake formation, stabilization
Generic daptomycin vial	Daptomycin	Sodium hydroxide and, in some products, sucrose	pH control and lyophilization support
Reconstituted vial	Daptomycin in solution	Sodium chloride from the diluent	Isotonic infusion vehicle
Premixed infusion	Daptomycin in infusion solution	Sodium chloride or another validated vehicle	Ready-to-administer delivery
Future long-acting or concentrated product	Daptomycin	Stabilizer, buffer, surfactant, tonicity agent, or depot excipient	Extended stability or modified administration

The U.S. label for Cubicin identifies sodium hydroxide as an inactive ingredient. Cubicin RF contains sucrose and sodium hydroxide. Generic labels differ, so excipient composition must be assessed product by product rather than inferred from the reference product.[1,2]

Why is daptomycin formulation-sensitive?

Daptomycin is a cyclic lipopeptide with calcium-dependent antibacterial activity. Its amphiphilic structure can create formulation challenges involving:

• Self-association and oligomerization
• Adsorption to containers and administration components
• Concentration-dependent aggregation
• Sensitivity to pH and ionic conditions
• Freeze-thaw stress
• Light and thermal degradation
• Interaction with divalent cations
• Reconstitution time and foaming
• Incompatibility with selected diluents or co-administered drugs

These characteristics make excipient selection a product-development issue rather than a simple cost-of-goods decision.

What is the FDA regulatory status of daptomycin?

Daptomycin is an FDA-approved antibacterial supplied as an intravenous injection or infusion. Cubicin was approved for complicated skin and skin-structure infections and later for Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis.[1]

Daptomycin is approved for adult indications and selected pediatric populations, depending on the product label. The FDA-approved dose depends on the indication and patient population. Common adult regimens include 4 mg/kg once daily for complicated skin infections and 6 mg/kg once daily for bacteremia and right-sided endocarditis.[1]

The product is administered intravenously. It is not an oral drug, and its commercial value is concentrated in hospital, infusion-center, and outpatient parenteral antimicrobial therapy channels.

What diluents are used with daptomycin?

The reference labeling supports reconstitution with 0.9% sodium chloride injection. The reconstituted solution is then administered by intravenous infusion. Product-specific instructions control the permitted diluent, concentration, storage period, and administration time.[1]

Dextrose-containing diluents should not be assumed to be interchangeable with saline. Compatibility depends on the specific formulation, concentration, container, and exposure time. A premixed product must generate its own stability and compatibility package rather than rely solely on the vial label.

What patents protect daptomycin and its formulations?

The original daptomycin composition and manufacturing patent estate is largely expired in the United States. The leading commercial product, Cubicin, lost primary small-molecule-style market exclusivity years ago, and FDA-approved generic daptomycin products entered the market.

Representative historical patents associated with daptomycin include patents covering the antibiotic complex, purification, compositions, and methods of treatment. Their commercial relevance has generally ended because the principal terms expired before or during the generic-entry period. The remaining opportunity is not ownership of the basic daptomycin molecule. It is the creation of separately patentable delivery, formulation, container, or manufacturing technology.

Patent category	Historical scope	Current strategic value
Daptomycin composition patents	The antibiotic complex and related compounds	Low after expiration
Fermentation and purification patents	Production and isolation of daptomycin	Low to moderate, depending on process claims
Treatment-method patents	Dosing and treatment of bacterial infections	Limited where expired; potentially relevant only for new, defensible indications
Lyophilized formulation patents	Stabilizers, pH, cake structure, reconstitution	Moderate if claims are narrow but clinically useful
Premixed-solution patents	Concentration, container, storage, and administration	Moderate to high if stability data support differentiation
Device and administration patents	Closed-system transfer, dual-chamber, infusion delivery	Moderate, usually in combination with formulation claims
Manufacturing-process patents	Yield, impurity control, crystallization, or scale-up	Moderate where the process produces measurable quality or cost advantages

Patent term extensions and pediatric exclusivity must be evaluated from the specific patent and approval record. They do not restore protection to the basic product after broad generic entry.

When did daptomycin lose exclusivity?

Daptomycin’s original U.S. market exclusivity ended before the current generic market structure formed. Cubicin generated substantial revenue during the protected period, but generic competition materially changed pricing and purchasing behavior after FDA approvals of abbreviated new drug applications.

The relevant commercial timeline is:

Event	Approximate timing	Commercial effect
Daptomycin discovery and early development	1980s-1990s	Creation of the active-ingredient and process estate
FDA approval of Cubicin	2003	Launch of branded intravenous daptomycin
Expansion into bacteremia and endocarditis	2006	Broader hospital and infectious-disease use
Core composition and treatment patents	Expired over the following decade	Reduced protection for the reference product
Generic approvals and launches	Mid-2010s onward	Rapid price and share pressure
Current market	Generic-dominated	Value shifts to supply reliability, formulation, and service

Merck reported Cubicin sales of more than $1 billion annually before generic erosion. The revenue base has since shifted from branded product economics to generic volume, hospital contracting, and differentiated delivery formats.[4]

What is the Orange Book status of daptomycin?

The FDA Orange Book is the primary source for listed patents, exclusivity, therapeutic-equivalence ratings, and approved reference products. Daptomycin’s commercial market is dominated by abbreviated new drug applications referencing the approved daptomycin injection products.

The key Orange Book implications are:

1. The product is eligible for generic competition through the ANDA pathway.
2. The active-ingredient patent estate does not provide a durable barrier to generic entry.
3. Any remaining listed patent must be assessed by product, dosage form, and approval status.
4. Formulation changes that create a new drug product may require an NDA or 505(b)(2) strategy rather than a conventional ANDA.
5. A new excipient combination is not automatically protected merely because it differs from the reference product.

A formulation sponsor seeking protection should focus on claims that connect the excipient system to measurable performance, such as extended stability, reduced aggregation, improved recovery after reconstitution, lower adsorption, or a materially shorter preparation process.

What formulation patents could protect a new daptomycin product?

The most defensible formulation claims would cover a defined combination of composition and performance. Broad claims to "daptomycin with a stabilizer" are vulnerable unless supported by unexpected technical results.

Lyophilized-vial patents

Potential claim elements include:

• A specified daptomycin concentration
• A defined sucrose-to-drug ratio
• A narrow pH range
• A selected buffer or buffer-free system
• Residual-moisture limits
• Cake-collapse resistance
• Reconstitution time
• Limits on high-molecular-weight impurities
• Stability after temperature excursion
• Reduced foaming during reconstitution

The strongest patent package would connect a specific excipient ratio to a demonstrated improvement over both the reference product and generic controls.

Premixed liquid patents

Premixed daptomycin could offer higher commercial value than a conventional vial if it remains stable for a commercially useful period. Potential claims could cover:

• Daptomycin concentration
• Saline or alternative infusion vehicle
• Container material
• Oxygen headspace
• Overfill volume
• Storage temperature
• Light protection
• Shelf life
• In-line filtration
• Low-sorption tubing
• Administration-ready presentation

A liquid product must address the chemical and physical stability limitations that explain why the original commercial product was supplied as a lyophilized powder.

Dual-chamber and closed-system products

A dual-chamber bag or vial could separate daptomycin from the infusion vehicle until administration. This approach may protect a product through a combination of:

• Chamber configuration
• Break-seal design
• Mixing sequence
• Reconstitution volume
• Container closure
• Terminal sterilization strategy
• Delivery-device compatibility

The commercial advantage is reduced pharmacy compounding and fewer preparation steps. The patent value depends on whether the configuration is technically necessary and difficult to design around.

How strong is the daptomycin patent estate?

The original estate is weak for blocking generic daptomycin. A new excipient-centered estate could be moderate if it meets three conditions:

1. The formulation solves a documented stability or workflow problem.
2. The claims require a specific composition or process that is not routine.
3. The product demonstrates a meaningful clinical, operational, or economic benefit.

Asset	Patent strength	Reason
Basic daptomycin composition	Low	Mature and largely expired
Conventional sucrose-stabilized vial	Low	Likely vulnerable to obviousness and design-around arguments
Novel lyophilized composition with validated stability	Moderate	Technical results can support non-obviousness
Ready-to-use liquid daptomycin	Moderate to high	Stability and container interaction create technical barriers
Room-temperature product	High potential	Requires substantial stability evidence and may reduce cold-chain dependence
Long-acting injectable	High potential but high risk	Requires new pharmacology, delivery technology, and clinical development
New manufacturing process	Moderate	Protection depends on process specificity and product-by-process limitations

Which companies are challenging or competing with daptomycin?

The competitive field includes:

• Generic daptomycin manufacturers
• Branded and generic lipoglycopeptide products
• Long-acting anti-infectives
• Hospital-administered vancomycin
• Ceftaroline and other anti-MRSA agents
• Outpatient infusion providers
• Contract manufacturers and specialty injectable suppliers

Daptomycin competes on bacteremia treatment, MRSA coverage, once-daily dosing, renal-dose management, and outpatient suitability. It competes against vancomycin on monitoring burden and nephrotoxicity considerations, while newer long-acting products compete on reduced administration frequency.

Its clinical limitation is that daptomycin is not used for pneumonia because pulmonary surfactant inhibits its activity.[1] This restricts the addressable market compared with broad-spectrum hospital antibiotics.

What commercial opportunities exist for daptomycin excipients?

1. Ready-to-administer premixed infusion

A stable premixed bag could reduce pharmacy labor, preparation errors, and dose-delivery delays. The principal barriers are liquid stability, container compatibility, particulate control, and shelf life.

2. Room-temperature stability

A product that tolerates controlled room-temperature storage could reduce cold-chain cost and improve deployment in outpatient, long-term-care, and emergency settings. The technical burden is high because stability must be demonstrated across concentration, packaging, transport, and temperature-excursion conditions.

3. Faster reconstitution

A vial that reconstitutes in less time and produces less foaming could have measurable value in high-volume hospital pharmacies. The benefit is operational rather than clinical, so pricing power would depend on workflow savings and purchasing contracts.

4. Low-sorption delivery systems

Daptomycin recovery can be affected by tubing, filters, and container materials. A validated low-sorption container and administration set could reduce dose loss and improve dose consistency. The strongest opportunity would combine a formulation with a proprietary or qualified delivery system.

5. Pediatric and weight-based presentations

Smaller vial sizes, higher-concentration presentations, and reduced wastage could improve pediatric and low-dose use. These products may have limited patent value but can create contracting advantages and reduce hospital inventory costs.

6. Outpatient parenteral antimicrobial therapy

An excipient system that supports longer refrigerated storage after reconstitution or dilution could support home infusion and ambulatory pump use. The commercial case depends on stability in the actual pump reservoir and administration set, not only in the original vial.

7. Manufacturing and impurity control

Process improvements that reduce daptomycin-related impurities, increase yield, or improve lot consistency can lower cost and support a differentiated quality profile. Process patents are most valuable when they are difficult to detect from the finished product and difficult to design around at commercial scale.

What generic launch risks exist for a new daptomycin formulation?

A sponsor developing a differentiated product faces several generic-entry risks:

• Generic manufacturers may copy the broad formulation concept after publication.
• A 505(b)(2) product may face an ANDA referencing the same active ingredient.
• Excipients with established parenteral use may weaken novelty arguments.
• Hospital buyers may reject a premium unless labor or wastage savings are quantifiable.
• A new container or delivery device may require separate compatibility work.
• A successful product may create a narrow market because low-cost vial products remain adequate for many hospitals.

The best protection is a layered portfolio covering composition, preparation process, container, administration method, and measurable stability performance.

What Paragraph IV and litigation issues affect daptomycin?

Daptomycin’s major generic-entry disputes occurred during the transition from branded Cubicin to generic supply. Paragraph IV certifications, patent settlements, and launch timing were commercially relevant during that period. The market now reflects mature generic competition rather than a pending core-product exclusivity event.

For a new excipient product, litigation risk would more likely concern:

• Obviousness of the excipient combination
• Written description and enablement
• Inherency of stability results
• Patent-term and Orange Book listing strategy
• Whether the product is properly eligible for ANDA substitution
• Whether a device or container claim is listed or enforceable
• Whether a generic product infringes performance-based formulation claims

Settlement agreements involving legacy Cubicin patents should not be treated as current barriers unless a particular agreement contains continuing obligations that affect the product or market.

Is biosimilar risk relevant to daptomycin?

Daptomycin is not primarily exposed to biosimilar risk. It is marketed through the small-molecule generic framework, including ANDAs, rather than the conventional biosimilar pathway.

The commercial risk is generic substitution and price erosion. A differentiated daptomycin product would need to establish value through formulation performance, workflow reduction, supply reliability, or a new dosing model.

How does daptomycin compare with competing anti-MRSA drugs?

Attribute	Daptomycin	Vancomycin	Long-acting lipoglycopeptides
Administration	Daily IV dosing	IV dosing with monitoring	Infrequent dosing for selected products
Pulmonary infection use	Not suitable for pneumonia	Commonly used	Product- and indication-dependent
Monitoring burden	Creatine phosphokinase and renal monitoring	Drug-level and renal monitoring	Lower administration frequency
Formulation opportunity	Premix, stability, low-sorption delivery	Premix and infusion optimization	Long-acting depot systems
Generic pressure	High	High	Varies by product
Patent opportunity	Excipient and delivery differentiation	Delivery and formulation	Composition, depot, and regimen claims
Main commercial buyer	Hospitals and infusion providers	Hospitals	Hospitals, specialty care, and outpatient providers

Daptomycin’s strongest positioning remains once-daily treatment for serious Gram-positive infections when clinicians want to avoid some limitations of vancomycin therapy. Its excipient opportunity is therefore tied to reducing the logistical cost of repeated intravenous administration.

What is the investment case for daptomycin excipient technology?

The investment case is strongest for a product that has:

• A validated shelf-life extension
• A premixed or ready-to-administer presentation
• Demonstrated compatibility with home-infusion systems
• Reduced pharmacy preparation time
• Lower product wastage
• A defensible patent portfolio
• A clear 505(b)(2) or other regulatory route
• Manufacturing economics that support a premium over generic vials

The investment case is weak for a conventional vial with minor excipient changes and no demonstrated performance advantage. Generic price pressure makes an undifferentiated lyophilized product difficult to commercialize.

Key Takeaways

• Daptomycin is a mature generic injectable with limited remaining value in the original active-ingredient patent estate.
• Sodium hydroxide is commonly used for pH adjustment; sucrose is present in some reference and generic presentations.
• The strongest formulation opportunities are premixed infusion, room-temperature stability, faster reconstitution, low-sorption delivery, and outpatient-use compatibility.
• New excipient patents need composition-specific claims supported by stability, reconstitution, impurity, or container-performance data.
• Daptomycin is exposed primarily to generic competition, not conventional biosimilar competition.
• The commercial opportunity is operational: fewer preparation steps, lower wastage, improved supply reliability, and lower total administration cost.
• A conventional excipient substitution without unexpected technical results is unlikely to create durable exclusivity.

FAQs

Can sucrose be replaced in a daptomycin formulation?

Yes. Sucrose can potentially be replaced with another lyoprotectant or stabilizer, but the substitute must preserve potency, impurity limits, reconstitution performance, cake integrity, and container compatibility.

Can daptomycin be formulated as a ready-to-use liquid?

Potentially, but the liquid product must overcome stability and aggregation constraints that are avoided by lyophilization. Container material, concentration, pH, storage temperature, and oxygen exposure are central development variables.

Does daptomycin require a surfactant?

Not necessarily. A surfactant may reduce adsorption or interfacial stress, but its inclusion can introduce new risks involving oxidation, impurities, extractables, and regulatory qualification.

Can an excipient patent block generic daptomycin?

Only if the generic product practices enforceable claims. A patent limited to a specific excipient combination, concentration, container, or process may not block conventional lyophilized daptomycin products.

Is a daptomycin premix commercially attractive for hospitals?

Yes, where it reduces pharmacy compounding, preparation time, dose wastage, or cold-chain complexity. The product must demonstrate enough operational savings to justify a premium over generic vials.

References

1. U.S. Food and Drug Administration. (2023). Cubicin (daptomycin for injection) prescribing information.
2. U.S. Food and Drug Administration. (2023). Cubicin RF (daptomycin for injection) prescribing information.
3. U.S. Food and Drug Administration. (2024). DailyMed: Daptomycin for injection labels. National Library of Medicine.
4. Merck & Co., Inc. (2015). Annual report for the fiscal year ended December 31, 2015.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.